Calidi Biotherapeutics Q2 2024 GAAP EPS $(1.40) Beats $(1.45) Estimate
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics (AMEX:CLDI) reported a Q2 2024 GAAP EPS of $(1.40), beating the analyst consensus estimate of $(1.45) by 3.45%.
August 13, 2024 | 9:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics reported a Q2 2024 GAAP EPS of $(1.40), which is better than the analyst estimate of $(1.45). This positive earnings surprise may boost investor confidence in the short term.
The company's reported EPS was better than expected, which is generally seen as a positive indicator for the stock price. This could lead to a short-term increase in investor confidence and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100